Sanara MedTech (SMTI) grows revenue, posts Q2 loss amid pending MIMEDX deal
Sanara MedTech (Nasdaq: SMTI) reported Q2 2026 net revenue of $28.1 million, up 9% year over year, with gross profit of $26.2 million and gross margin of 93%. It posted a net loss from continuing operations of $0.4 million ($0.05 per diluted share). Cash was $15.4 million and long-term debt $46.5 million. After quarter-end, Sanara said it expects to be acquired by MIMEDX, subject to closing conditions.
How this was made
The 30-second read
Why it matters
Traders can weigh near-term deal optionality against ongoing operating expense pressure and financing costs, while also tracking the planned market introduction of OsStic in Q1 2027.
Market read
Fresh Q2 numbers show continued revenue growth and strong gross margin, while the newly disclosed acquisition agreement is the more material catalyst for repricing.
What to watch
The release highlights higher SG&A and interest expense tied to the CRG term loan; deal economics could be pressured if financing or liabilities are less favorable than implied.
Background
Sanara MedTech (Nasdaq: SMTI) released unaudited Q2 2026 financial results and stated that it entered an agreement expected to be acquired by MIMEDX, subject to customary closing conditions.
Ticker impact
Sanara MedTech reported Q2 2026 results with 9% revenue growth and disclosed an expected acquisition by MIMEDX, pending closing conditions.
Near-term upside bias on deal optimism, tempered by uncertainty around closing conditions and integration risk.
The article combines a fresh earnings datapoint (revenue, margin, EBITDA) with a newly announced transformational acquisition agreement, which typically drives repricing more than the quarterly numbers alone.
Market effects
Could increase attention on regenerative medicine and surgical product suppliers, especially collagen particulate, wound irrigation, and bone fixation categories.
Limited direct regional read-through; primarily a US-listed small-cap medtech deal narrative.
Modest global relevance given company size, but deal could affect competitive positioning in surgical regenerative medicine markets.
Counterpoint
Revenue growth and high gross margin may not translate into deal value if diligence reveals margin sustainability or distributor concentration issues.
Key entities
- companySanara MedTech Inc.
Nasdaq-listed medical technology company reporting Q2 2026 results and announcing a pending acquisition by MIMEDX.
- companyMIMEDX
Wound care and surgical regenerative medicine provider expected to acquire Sanara under a transformational agreement.
- creditorCRG Servicing LLC
Term loan servicer referenced as driving higher interest expense in Q2 2026 due to cash vs paid-in-kind interest.
